CA2509042A1 - Novel mch receptor antagonists - Google Patents

Novel mch receptor antagonists Download PDF

Info

Publication number
CA2509042A1
CA2509042A1 CA002509042A CA2509042A CA2509042A1 CA 2509042 A1 CA2509042 A1 CA 2509042A1 CA 002509042 A CA002509042 A CA 002509042A CA 2509042 A CA2509042 A CA 2509042A CA 2509042 A1 CA2509042 A1 CA 2509042A1
Authority
CA
Canada
Prior art keywords
biphenyl
carboxylic acid
ethylsulfanylmethyl
phenoxy
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002509042A
Other languages
English (en)
French (fr)
Inventor
James Ronald Gillig
Lawrence Joseph Heinz
Michael Dean Kinnick
Yen-Shi Lai
John Michael Junior Morin
Nancy June Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2509042A1 publication Critical patent/CA2509042A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002509042A 2002-12-11 2003-12-03 Novel mch receptor antagonists Abandoned CA2509042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43270102P 2002-12-11 2002-12-11
US60/432,701 2002-12-11
PCT/US2003/037071 WO2004052848A1 (en) 2002-12-11 2003-12-03 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
CA2509042A1 true CA2509042A1 (en) 2004-06-24

Family

ID=32507985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002509042A Abandoned CA2509042A1 (en) 2002-12-11 2003-12-03 Novel mch receptor antagonists

Country Status (9)

Country Link
US (1) US7132456B2 (enExample)
EP (1) EP1572637A1 (enExample)
JP (1) JP2006509801A (enExample)
CN (1) CN1726189A (enExample)
AU (1) AU2003302925A1 (enExample)
BR (1) BR0316948A (enExample)
CA (1) CA2509042A1 (enExample)
MX (1) MXPA05006272A (enExample)
WO (1) WO2004052848A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
CN101184732B (zh) * 2005-03-28 2012-05-16 株式会社半导体能源研究所 蒽衍生物、发光元件用材料、发光元件、发光装置和电子器件
US7731377B2 (en) * 2006-03-21 2010-06-08 Semiconductor Energy Laboratory Co., Ltd. Backlight device and display device
US7772162B2 (en) 2006-03-27 2010-08-10 Board Of Regents, The University Of Texas System Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
US20070225176A1 (en) * 2006-03-27 2007-09-27 Pope Gary A Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
WO2008026614A1 (en) * 2006-08-30 2008-03-06 Semiconductor Energy Laboratory Co., Ltd. Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device
US7723722B2 (en) 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
RU2009138310A (ru) * 2007-03-23 2011-04-27 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем (Us) Способ обработки формации растворителем
US8403050B2 (en) * 2007-03-23 2013-03-26 3M Innovative Properties Company Method for treating a hydrocarbon-bearing formation with a fluid followed by a nonionic fluorinated polymeric surfactant
US20080286445A1 (en) * 2007-05-17 2008-11-20 Semiconductor Energy Laboratory Co., Ltd. Composition, and method of fabricating light-emitting element
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2238312A4 (en) * 2007-11-30 2011-08-17 Univ Texas METHOD FOR IMPROVING THE PRODUCTIVITY OF OIL EXTRACTION OILS
WO2010005066A1 (en) * 2008-07-08 2010-01-14 Semiconductor Energy Laboratory Co., Ltd. Carbazole derivative, light-emitting element material, light-emitting element, and light-emitting device
EP2166001B1 (en) * 2008-09-19 2011-07-20 Semiconductor Energy Laboratory Co., Ltd. Carbazole Derivative and Method for Producing the Same
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102844041B1 (ko) 2016-02-26 2025-08-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
KR20260094346A (ko) 2023-11-09 2026-06-22 셰브론 필립스 케미컬 컴퍼니 엘피 크로뮴 촉매 활성화를 위한 시스템 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) * 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3928449A (en) * 1969-04-03 1975-12-23 Sandoz Ag Aminoalkoxy-terphenyls and the salts thereof
LU78484A1 (de) * 1977-11-10 1979-06-13 Ciba Geigy Ag Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen
DE2752361A1 (de) 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
WO2004052848A1 (en) 2004-06-24
EP1572637A1 (en) 2005-09-14
CN1726189A (zh) 2006-01-25
MXPA05006272A (es) 2005-08-19
US7132456B2 (en) 2006-11-07
BR0316948A (pt) 2005-10-18
US20060052449A1 (en) 2006-03-09
AU2003302925A1 (en) 2004-06-30
JP2006509801A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2004052848A1 (en) Novel mch receptor antagonists
AU716122B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
RU2673245C2 (ru) Производные 4-аминометилбензойной кислоты
CN105358532B (zh) 杂环化合物和它们的使用方法
CN106999451A (zh) 双环化合物
TW202220959A (zh) 經取代哌啶化合物及其用途
JP2013536178A (ja) アリールスルホンアミド誘導体、組成物、および使用方法
CA2613458A1 (en) Compounds with activity at retinoic acid receptors
JP2016538309A (ja) 抗がん剤としての官能化及び置換インドール
CA2910255A1 (en) Inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof
CN101616892A (zh) 用于治疗铁失调的三环化合物
WO2003087045A1 (en) Novel methoxybenzamide compounds for use in mch receptor related disorders
US9447044B2 (en) Thioaryl derivatives as GPR120 agonists
CA2542220A1 (en) Novel mch receptor antagonists
US20110275663A1 (en) N-Acylthiourea and N-Acylurea Inhibitors of the Hedgehog Protein Signalling Pathway
CA3096059A1 (en) Opioid receptor modulators and products and methods related thereto
CA2825700A1 (en) Alpha-ketoheterocycles and methods of making and using
ES2787625T3 (es) Activadores de hERG policíclicos
ES2629501T3 (es) Derivados de pirrol bicíclicos útiles como agonistas de GPR12O
BRPI0610240A2 (pt) compostos, composição farmacêutica, uso do composto, método de tratamento de uma doença, e, processo para preparação de um composto
ES2348838T3 (es) Compuestos de cicloalquilideno como moduladores slectivos del receptor de estrã“genos.
CN106061943B (zh) 可用作gpr120的激动剂的双环吡咯类衍生物
JP2008517930A (ja) GalR1のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
CN106431898A (zh) 苯丙酸类衍生物的合成和用途
HK1230597B (en) Bicyclic pyrrole derivatives useful as agonists of grp120

Legal Events

Date Code Title Description
FZDE Discontinued